Merck & Co., Inc. (MRK) Holdings Held by State Farm Mutual Automobile Insurance Co.

State Farm Mutual Automobile Insurance Co. held its position in shares of Merck & Co., Inc. (NYSE:MRK) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,145,800 shares of the company’s stock at the end of the 2nd quarter. Merck & Co., Inc. comprises approximately 1.3% of State Farm Mutual Automobile Insurance Co.’s holdings, making the stock its 24th largest holding. State Farm Mutual Automobile Insurance Co. owned 0.55% of Merck & Co., Inc. worth $970,695,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of MRK. RB Capital Management LLC lifted its stake in shares of Merck & Co., Inc. by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after buying an additional 23 shares in the last quarter. Baystate Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 0.4% in the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after buying an additional 27 shares in the last quarter. Bath Savings Trust Co lifted its stake in shares of Merck & Co., Inc. by 0.5% in the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after buying an additional 28 shares in the last quarter. Camelot Portfolios LLC lifted its stake in shares of Merck & Co., Inc. by 0.4% in the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after buying an additional 33 shares in the last quarter. Finally, Stillwater Investment Management LLC lifted its stake in shares of Merck & Co., Inc. by 0.8% in the second quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock worth $296,000 after buying an additional 38 shares in the last quarter. 73.84% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.25% of the stock is owned by insiders.

Several brokerages have recently issued reports on MRK. TheStreet downgraded shares of Merck & Co., Inc. from a “b” rating to a “c” rating in a research note on Monday, November 27th. Bank of America began coverage on shares of Merck & Co., Inc. in a research note on Tuesday, November 28th. They issued a “buy” rating and a $64.00 target price on the stock. Deutsche Bank dropped their target price on shares of Merck & Co., Inc. from $62.00 to $59.00 and set a “hold” rating on the stock in a research note on Friday, November 24th. Sanford C. Bernstein reiterated a “buy” rating and issued a $64.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, November 15th. Finally, Cowen reiterated a “hold” rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $66.29.

Merck & Co., Inc. (MRK) traded down $1.42 on Thursday, hitting $54.35. 20,245,900 shares of the stock traded hands, compared to its average volume of 9,695,972. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Co., Inc. has a 1 year low of $53.63 and a 1 year high of $66.80. The stock has a market capitalization of $151,941.86, a PE ratio of 14.34, a price-to-earnings-growth ratio of 2.58 and a beta of 0.76.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same period in the previous year, the company earned $1.07 earnings per share. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. equities analysts predict that Merck & Co., Inc. will post 3.95 earnings per share for the current year.

Merck & Co., Inc. announced that its Board of Directors has approved a share buyback plan on Tuesday, November 28th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 8th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 3.53%. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend is Thursday, December 14th. Merck & Co., Inc.’s payout ratio is presently 112.58%.

WARNING: This piece of content was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3079973/merck-co-inc-mrk-holdings-held-by-state-farm-mutual-automobile-insurance-co.html.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.